BMS and Pfizer file 16 Eliquis patent lawsuits to waylay generic makers

Fierce Pharma ------- Pfizer and Bristol-Myers Squibb are erecting a wall of patent infringement lawsuits that they hope will slow the advance of generic versions of their shared blockbuster Eliquis. The partners this week filed suit against 13 generic makers, on top of three filed last week, reports the Delaware Law Weekly, naming companies that include Mylan, Dr. Reddy’s Laboratories and Accord Healthcare.The two have plenty to protect in the stroke and blood clot preventer. It earned BMS about $3.3 billion last year, up nearly 60% from the $1.9 billion earned the year before. Pfizer enjoyed $1.6 billion from the drug. To get more in depth information click on the picture below to read the article.